Rosucard

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rosucard

What is Rosucard?

Rosucard is a pharmaceutical medication belonging to the class of drugs known as statins, or HMG-CoA reductase inhibitors. It contains the active substance rosuvastatin and is primarily used to manage lipid levels in the blood.

Mechanism of Action

The medication works by inhibiting a specific enzyme in the liver that is responsible for the biological production of cholesterol. By reducing the internal production of cholesterol, it helps lower the levels of low-density lipoprotein (LDL) cholesterol—often referred to as "bad" cholesterol—and triglycerides. Simultaneously, it can contribute to a moderate increase in high-density lipoprotein (HDL) cholesterol, known as "good" cholesterol.

Therapeutic Purpose

Rosucard is prescribed to address various lipid-related conditions, including:

  • Primary Hypercholesterolemia: Used when a patient has elevated levels of cholesterol in the blood.
  • Mixed Dyslipidemia: Used when there are imbalances in various types of blood fats.
  • Prevention of Cardiovascular Events: Used in individuals who are at a high risk of experiencing a first-time heart attack or stroke, particularly those with multiple risk factors such as age, high blood pressure, or a family history of heart disease.
  • Slowing Atherosclerosis: It may be used to slow the progression of plaque buildup in the arterial walls, a condition that can lead to narrowed or hardened arteries.

Role in Management

This medication is intended to be used as an adjunct to a lipid-lowering diet. It serves as a pharmacological intervention when lifestyle modifications, such as nutritional changes and physical exercise, are insufficient on their own to bring cholesterol levels within a target range.

Regulatory References

  1. NIH DailyMed Monograph
  2. MedlinePlus Drug Information

What side effects are possible with Rosucard?

Possible Side Effects and Safety Information for Rosucard (Rosuvastatin)

This section summarizes the official adverse reactions and safety restrictions for Rosucard, as documented in government regulatory labeling (e.g., FDA, EMA). The medicine’s safety profile is categorized by frequency and the body system affected.

Adverse Reactions and Organ Systems

Common Adverse Reactions (may affect up to 1 in 10 people) typically involve the musculoskeletal and nervous systems, including Myalgia (muscle pain), Headache, Constipation, and Nausea. New-onset Diabetes Mellitus is also classified as common. Less common effects include Proteinuria (protein in urine) and skin reactions (e.g., rash, itching).

Serious Adverse Reactions

Official labeling highlights the risk of rare but serious events, most notably Rhabdomyolysis (severe muscle breakdown) and potential Fatal and Non-fatal Hepatic Failure. The risk of these muscle events is documented to be higher at the maximum approved dose (40 mg).

Safety Restrictions and Special Populations

Regulatory Contraindications strictly prohibit the use of Rosucard in patients with Active Liver Disease, Severe Renal Impairment (creatinine clearance < 30 mL/min), or diagnosed Myopathy. It is also contraindicated during Pregnancy and Lactation.

Population-Specific Considerations

  • Asian Ancestry: Official documents note increased systemic exposure, recommending a lower starting dose (5 mg) and often contraindicating the 40 mg dose.
  • Geriatric Patients (65 years): This group is recognized as having predisposing factors for Myopathy and Rhabdomyolysis.

Safety Monitoring: The regulatory label recommends assessment of liver enzymes before starting therapy and as clinically indicated thereafter. Patients are advised to report any unexplained muscle pain, weakness, or tenderness, especially if accompanied by fever.

Overdose and Emergency Response

Rosucard Overdose and when to seek help

Official regulatory documentation states that no specific, characteristic symptoms of an acute Rosuvastatin overdose are explicitly documented. Despite the lack of an established symptom profile, regulatory bodies mandate that any known or suspected exposure exceeding the prescribed dosage requires immediate medical attention. You must contact emergency services or a Poison Center expert right away.

The primary concern in an overdose situation relates to the drug class risk, which involves the potential for severe adverse events, including rhabdomyolysis and muscle toxicity (myopathy).

Overdose Status Regulatory Action Required
Antidote No specific antidote is known.
Management Management is defined as symptomatic and supportive.
Clearance Hemodialysis is not expected to significantly enhance drug clearance due to extensive protein binding.
Monitoring Continuous monitoring is necessary, particularly for Creatine Kinase (CK) levels and renal function, to identify and manage the potential onset of rhabdomyolysis.

The management strategy is therefore focused entirely on symptom control and crucial observation, guided by the non-existence of a specific reversal agent. Prompt action ensures appropriate supportive care is administered to mitigate severe, class-related complications, including the potential for elevated CK levels and liver enzyme abnormalities.

Therapeutic Uses of Rosucard

The primary therapeutic role of Rosucard (Rosuvastatin) is applied in addressing symptoms related to systemic imbalance (lipid disorders) and supporting the long-term management of cardiovascular risk.

The medication is used to help manage high cholesterol and risk factors associated with heart problems. Rosucard is commonly used to manage the systemic lipid disorder of primary hypercholesterolemia (high cholesterol) and mixed dyslipidemia. It helps address the systemic imbalance of blood fats, assisting with Low-Density Lipoprotein Cholesterol (LDL-C) and triglycerides, and may assist with High-Density Lipoprotein Cholesterol (HDL-C) levels. This use is generally applied when initial management through diet and increased physical activity alone are insufficient to address the lipid levels.

The medication contributes to easing the symptom burden associated with persistent cholesterol elevation, where long-term therapeutic support is considered relevant. This includes the management of inherited high cholesterol, mixed dyslipidemia, and primary hypercholesterolemia.


Quick Fact: Relief for Invisible Blood Fat Abnormalities The therapeutic support provided by Rosucard contributes to easing the overall symptom load by assisting with maintaining functional stability during long-term symptomatic periods, and supports patients during episodes of heightened discomfort.


Regulatory References

  1. Rosuvastatin: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Rosucard eligibility is determined by specific regulatory criteria relating to age, medical history, and physiological status.

Populations Not Eligible (Contraindicated)

Use of Rosucard is strictly prohibited under the following conditions:

  • Active liver disease, including unexplained persistent elevations in liver enzyme levels.
  • Hypersensitivity to rosuvastatin or any other component of the product.
  • Women who are pregnant or may become pregnant.
  • Women who are nursing or breastfeeding.
  • Patients with pre-existing myopathy (muscle disease).
Age-Related Eligibility Condition-Specific Restrictions
Adults: Established use for various lipid disorders. Severe Renal Impairment (CrCl < 30 mL/min) is a contraindication in some regions; the maximum allowable dose is mathbf10 mg in the US.
Pediatrics: Approved for children mathbfge 8 years (HeFH) and mathbfge 7 years (HoFH). Safety is not established below these ages. Predisposing factors for myopathy require caution (e.g., advanced age, inadequately treated hypothyroidism, or a history of alcohol abuse).
Older Adults: Advanced age (mathbfge 65 years) is noted as a risk factor for muscle-related effects. Asian Patients should generally begin treatment at a mathbf5 mg starting dose due to increased drug exposure.

Connection to the overall eligibility profile: Official regulatory documents define who can and cannot use the medicine by establishing absolute exclusions related to liver disease and reproductive status. Eligibility is conditional upon specific organ function and the presence of comorbidities that may increase the risk of muscle toxicity, while also clearly defining the approved minimum ages for pediatric use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Rosucard (rosuvastatin) interacts with certain other medicines primarily by affecting the transport of rosuvastatin in the body or by increasing the risk of muscle-related adverse events.

Classification Examples of Interacting Medicines/Categories
Exposure-Increasing Interactions Cyclosporine, Gemfibrozil, certain Antivirals (e.g., Lopinavir/Ritonavir, Sofosbuvir/Velpatasvir), Regorafenib, Darolutamide
Additive Muscle Risk (Pharmacodynamic) Fibrates (e.g., Fenofibrate), Niacin (1 g/day)
Anticoagulant Effect Modification Coumarin Anticoagulants (e.g., Warfarin)

Interaction Details and Constraints

  • Transporter-Mediated Effects: Many clinically significant interactions occur because co-administered drugs inhibit hepatic transport proteins (OATP1B1, BCRP) responsible for Rosucard uptake and elimination. This inhibition significantly raises rosuvastatin levels in the bloodstream.
  • Contraindicated Combinations: Co-administration with Cyclosporine may be contraindicated or strictly limited to a very low daily dose of Rosucard due to substantial increases in rosuvastatin exposure.
  • Required Monitoring: Co-administration with Coumarin Anticoagulants requires monitoring of the International Normalised Ratio (INR) upon initiation and dosage changes of Rosucard.
  • Timing Separation: Aluminum and magnesium hydroxide antacids interfere with Rosucard absorption. To prevent reduced effectiveness, antacids must be taken at least 2 hours after the Rosucard dose.
  • Population Considerations: Higher systemic exposure is officially noted in Asian patients, which must be factored into interaction management when co-administering certain interacting medicines.

Mechanism of Action

Inhibition of Cholesterol Synthesis and Enhanced Clearance

Rosucard's active component, rosuvastatin, exerts its primary action by competitively inhibiting the enzyme HMG-CoA reductase in the liver. This enzyme catalyzes the rate-limiting step in the mevalonate pathway, which is the body's primary process for synthesizing cholesterol. This molecular blockade causes a drop in intracellular cholesterol, prompting the liver cells to upregulate LDL receptors on their surface. This systemic response increases the liver's capacity to capture and remove Low-Density Lipoprotein Cholesterol (LDL-C) particles from the circulating blood, leading to an alteration of lipid homeostasis.


Pleiotropic Effects on Vascular Signaling

Independent of its direct lipid-lowering cascade, rosuvastatin also engages pleiotropic mechanisms. By inhibiting HMG-CoA reductase, the drug limits the production of isoprenoid intermediates that are essential for the activity of certain cell-signaling proteins (like Rho/Rac). Modulating this signaling pathway results in functional changes to the vascular endothelium and leads to an increased presence of nitric oxide (NO). This dual-mechanistic action contributes to changes in physiological signaling within the circulatory system by reducing key inflammatory signals.

Dosage and Administration Information

How Rosucard is Used: Official Administration and Dosing

Rosucard (rosuvastatin) is prescribed for long-term management of lipid disorders and is used according to strict guidelines. Its use is standardized, continuous, and integrated with dietary management.


Administration and Scheduling

Instruction Official Guideline
Route of Administration Oral use only, as a film-coated tablet.
Dosing Frequency Once daily, taken at any time of day, with or without food.
Preparation The tablet must be swallowed whole.
Course Duration Intended for long-term, continuous therapy alongside a standard cholesterol-lowering diet.

Standard Dosing Regimens

Dosing begins with a specific starting amount and is adjusted over time based on the individual's response, which is assessed through follow-up blood tests.

Dosing Parameter Official Adult Instructions
Usual Starting Dose 10 mg or 20 mg once daily.
Maximum Dose 40 mg once daily (use reserved for specific cases).
Dose Adjustment Dose changes (titration) should not occur more frequently than every 2 to 4 weeks.

Population-Specific Use

Specific guidelines outline dosage restrictions for certain populations to ensure proper use:

  • Severe Renal Impairment (kidney dysfunction): The starting dose is limited to 5 mg, and the maximum daily dose should not exceed 10 mg.
  • Asian Descent: The recommended starting dose is 5 mg once daily, and the maximum dose may be restricted to 20 mg in some regions.

Recent Clinical Evidence

Rosucard: Recent Clinical Evidence

This summary provides a neutral overview of the research and clinical trial data for Rosuvastatin, the active ingredient in Rosucard, focusing on what studies have explored and observed, without providing clinical advice or therapeutic claims.


Evidence for the Study of High Cholesterol

The evidence base for Rosuvastatin was developed through short-term randomized controlled trials (RCTs) examining individuals with high cholesterol (hypercholesterolemia) and mixed dyslipidemia. These studies researched how key lipid biomarkers, including Low-Density Lipoprotein Cholesterol (LDL-C) and Total Cholesterol, changed over defined time intervals. The findings describe patterns observed in these studies where biomarkers showed changes in comparison to placebo or other therapies. Research exploring these blood measures is subject to the limitation that follow-up durations were often brief, restricting the direct connection to long-term clinical events.


Evidence for the Study of Cardiovascular Events

Rosuvastatin has been studied extensively in the context of cardiovascular events for both primary prevention (individuals at high risk but without established disease) and secondary prevention (those with existing heart problems). These long-term, large-scale trials examined the occurrence of Major Adverse Cardiovascular Events (MACE), which include non-fatal heart attack, non-fatal stroke, and arterial revascularization procedures that were performed. The research describes patterns of event incidence over observation periods that typically extend for several years. Comparative evidence directly against all other statins across all MACE endpoints is limited.


Evidence in Specific Patient Groups

Studies have also been evaluated to understand the evidence profile for specific populations, particularly children and adolescents with severe, inherited forms of high cholesterol, such as Heterozygous Familial Hypercholesterolemia (HeFH). These small-scale trials monitored lipid biomarker changes and growth over medium-term periods. The data for these patient groups remain insufficient for very long-term outcomes, and subgroup findings are uncertain due to modest sample sizes, reflecting the rare nature of these conditions. The full lifetime profile of the drug's context in these groups is not fully established.

Frequently Asked Questions (FAQ)

Common questions about Rosucard (FAQ)

Q: Is Rosucard used for things other than cholesterol?

A: Yes, official regulatory documents list its use for treating high cholesterol, and also for the prevention of major cardiovascular events (like heart attack and stroke) in specific patients considered to be at high risk. This indicates that regulatory documents describe its use for risk reduction beyond standard lipid goals.

Q: Is it common to feel tired when starting Rosucard?

A: Reports of general tiredness, sometimes described as asthenia or fatigue, have been noted as side effects during post-marketing surveillance. This effect is usually considered mild. Safety warnings emphasize that symptoms of concern should be discussed with a healthcare professional.

Q: Are there any common vitamins or supplements that interact with Rosucard?

A: Official product information notes that Rosucard may interact with the vitamin Niacin when taken in high doses, typically 1 g per day or more. This combination could potentially increase the risk of muscle-related adverse events. Other common vitamins or supplements are not specifically listed as major interactions in the official documentation.

Q: What happens if I miss a day of taking Rosucard?

A: According to the official patient information, if a dose is missed, patients are advised not to take an extra dose to compensate. Treatment involves resuming with the next regularly scheduled dose, and official guidance is to avoid taking two doses at once.

Q: What is the difference between Rosucard and generic rosuvastatin?

A: Rosuvastatin is the active ingredient in the brand name medicine, Rosucard. Regulatory agencies require that the generic version be bioequivalent, meaning it delivers the same amount of the active ingredient into the bloodstream at a comparable rate. The goal of this regulatory requirement is to ensure the drugs are therapeutically equivalent.

Q: What should I do if I experience unusual dark urine while on Rosucard?

A: The official warnings emphasize that unexplained muscle pain, weakness, or tenderness, particularly if accompanied by fever, is a symptom to be discussed with a healthcare provider. Dark urine can be a related sign of rhabdomyolysis (severe muscle breakdown), which is a rare but serious adverse reaction noted in the regulatory documents.

Q: What are the rules about drinking alcohol while taking Rosucard?

A: Regulatory information notes that the use of substantial quantities of ethanol (alcohol) may increase the risk of developing liver problems. A history of alcohol abuse is also recognized as a predisposing factor for muscle-related side effects. The medicine is contraindicated in patients with existing active liver disease.

Q: Are there any food restrictions besides grapefruit when taking Rosucard?

A: Official information states that the medicine can be taken with or without food. The primary restriction relates to certain antacids containing aluminum and magnesium hydroxide. Official guidance is that antacids should be taken at least two hours after the Rosucard dose to maintain proper absorption.

Q: Is Rosucard known to cause memory problems?

A: Regulatory sources report that there have been rare post-marketing reports of cognitive impairment, which can include memory loss or confusion, associated with statin use. These findings are based on post-marketing reports, and a direct causal link is not established in controlled clinical trials. The effects are generally described as non-serious and reversible upon stopping the medicine.

Q: When is Rosucard typically stopped or discontinued?

A: The medicine is generally intended for long-term, continuous therapy. According to regulatory documents, use is strictly contraindicated if a woman becomes pregnant or is breastfeeding, or if a patient develops active liver disease or myopathy. Any decision regarding discontinuation outside of these contraindications is made within the context of medical oversight.

Q: What is the purpose of the highest available dose of Rosucard?

A: The maximum approved dose of 40 mg is reserved for patients who require the most intensive cholesterol lowering, such as those with severe hypercholesterolemia (very high cholesterol levels). Official documentation indicates this dose is intended for those who have not achieved their treatment goals on lower doses.

Q: Is it common for people to stop taking Rosucard due to side effects?

A: In controlled clinical trials that led to regulatory approval, the official data indicates that approximately 3.7% of patients taking Rosucard discontinued treatment due to an adverse reaction. This indicates that discontinuation due to adverse reactions was necessary for a small percentage of patients studied.

Q: What should I know about using Rosucard and birth control pills?

A: Official drug interaction information notes that co-administration with oral contraceptives can increase the concentration of certain hormones (ethinyl estradiol and norgestrel) in the bloodstream. The potential interaction is a factor for consideration during the medical review of the patient's full regimen.

Q: How long does it typically take to see the effects of Rosucard on cholesterol levels?

A: Regulatory product information notes that the full therapeutic response is generally achieved within 2 to 4 weeks after starting the medicine or after a dose change. Regulatory guidelines often use this period as the minimum time to assess the effectiveness of the current dose.

How should Rosucard be stored and disposed of?

How to Store and Dispose of Rosucard (Rosuvastatin)

The storage and disposal of Rosucard must follow instructions provided in the official regulatory labeling to maintain drug potency and ensure public safety.


Storage Requirements

Rosuvastatin tablets must be kept at controlled room temperature, specifically between 20 C and 25 C. The medication should be protected from excessive heat and moisture and stored in its original container, which must be kept tightly closed. For safety, the product must be stored securely, out of the sight and reach of children.


Disposal Instructions

Unused or expired Rosucard should be discarded using a community drug take-back program. If no take-back program is available, the tablets can be mixed with an unappealing substance (like used coffee grounds) and sealed in a bag for disposal in the household trash. The medication should not be flushed down the toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rosucard found in:

A-Z Index: